Related Experiment Video

Updated: Jun 3, 2025

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

8.5K

HDAC6: Tumor Progression and Beyond

João Marcos Oliveira-Silva1,2, Leilane Sales de Oliveira1,2, João Vitor Marangoni Tagliéri1

  • 1Human Genetics Laboratory, Institute of Natural Sciences, Federal University of Alfenas (UNIFAL-MG), Alfenas, 37130-001, MG, Brazil.

Current Cancer Drug Targets
|January 9, 2025
PubMed

Insights

Histone Deacetylase 6 (HDAC6) is a promising cancer target due to its cytoplasmic role and non-histone targets. HDAC6 inhibitors show potential in treating various cancers and are advancing in clinical trials.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Histone Deacetylase 6 (HDAC6) is unique among HDACs, primarily located in the cytoplasm.
  • It possesses two catalytic domains and a distinct ubiquitin-binding domain.
  • HDAC6 deacetylates non-histone substrates like α-tubulin, HSP90, and cortactin.

Purpose of the Study:

  • To review the structural characteristics of HDAC6.
  • To elucidate the biological functions of HDAC6 in tumor progression.
  • To discuss the therapeutic potential of HDAC6 inhibitors in cancer treatment.

Main Methods:

  • Review of existing literature on HDAC6 structure and function.
  • Analysis of HDAC6's role in key cancer hallmarks.
  • Compilation of data from preclinical and clinical trials of HDAC6 inhibitors.

Main Results:

  • HDAC6 influences tumor invasion, metastasis, angiogenesis, drug resistance, stemness, and immune evasion.
  • Selective HDAC6 inhibitors are being investigated for solid and hematological tumors.
  • Several HDAC6 inhibitors have entered clinical trials with positive preliminary results.

Conclusions:

  • HDAC6 is a significant therapeutic target in oncology.
  • Targeting HDAC6 offers a promising strategy for cancer therapy.
  • Ongoing clinical trials are evaluating the efficacy of HDAC6 inhibitors.
Keywords:
HDAC6HSF1.clinical trialsselective inhibitorsolid tumorstherapeutic targets

More Related Videos

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

14.7K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.1K

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K